Introduction
============

Phospholipase A~2~ receptor 1 (PLA~2~R), an M-type PLA~2~ receptor, is a type I transmembrane glycoprotein with a molecular mass of 180 kDa^[@bib1]--[@bib4])^. It is composed of an extracellular portion consisting of an N-terminal cysteine-rich domain (CRD), a fibronectin-like type II (FNII) domain, a tandem repeat of 8 C-type lectin-like domains (CTLD), and a short intra-cellular C-terminal region (**[Fig. 1](#F1){ref-type="fig"}**)^[@bib1]--[@bib4])^.

![Schematic representation of T/C at rs3749117 and G/C at rs35771982 polymorphisms located in the C-type lectin-like domains (CTLD) 1 of PLA~2~R gene](jat-23-1227-g001){#F1}

The murine secretory phospholipase A~2~ (sPLA~2~), including sPLA~2~-IB, -IIA, -IIE, -IIF and -X, acts as a ligand for murine PLA~2~R^[@bib2],\ [@bib3],\ [@bib5])^. Murine PLA~2~R functions as a clearance receptor through internalization and degradation of bound sPLA~2~s^[@bib5]--[@bib8])^. In contrast, there are no reports showing that human sPLA~2~s bind to human PLA~2~R with high affinity. Thus, there is species-specificity in the ligand affinity of sPLA~2~ for PLA~2~R^[@bib9])^.

Bernard *et al.* recently showed that human PLA~2~R promotes senescence in fibroblasts and induces cancer cell death through a JAK2-mediated mechanism^[@bib10],\ [@bib11])^. We have recently shown that the extracellular portion of mouse PLA~2~R interacts with that of integrin *β*1 through collagen type I and that PLA~2~R induces collagen-dependent migration and proliferation of myofibroblasts through an integrin *β*1-mediated intracellular signaling mechanism^[@bib9],\ [@bib12])^. Our group and other researchers showed that collagen I binds to the FNII domain of PLA~2~R^[@bib9],\ [@bib12],\ [@bib13])^ and that the adjacent CTLD1 region modulates the collagen binding activity of FNII domain^[@bib9])^. We showed that PLA~2~R played a crucial role in healing post-MI myocardium^[@bib12])^. Thus, PLA~2~R appears to have multiple biological functions in a sPLA~2~-dependent or -independent fashion.

PLA~2~R was identified as a major antigen in idiopathic membranous nephropathy (IMN)^[@bib14])^. Circulating antibodies to PLA~2~R are present in 70% of patients with IMN^[@bib14])^. The anti-PLA~2~R1 antibody is likely to recognize the N-terminal region of PLA~2~R, consisting of the CRD, FNII domain, and CTLD 1 and 2^[@bib15],\ [@bib16])^. Furthermore, two nonsynonymous polymorphisms (rs3749117 and rs35771982) in the CTLD1 domain of the PLA~2~R gene have been linked to the occurrence of IMN in patients (**[Fig. 1](#F1){ref-type="fig"}**)^[@bib17],\ [@bib18])^. It has been suggested that two amino acid substitutions (Met292Val encoded by SNP rs3749117 and His300Asp encoded by rs35771982) in CTLD1 may change its configuration, facilitating antigenicity of the N-terminal region of the variant PLA~2~R^[@bib17],\ [@bib18])^.

It is unknown whether these nonsynonymous polymorphisms in CTLD1 of the PLA~2~R gene alter the biological functions of PLA~2~R. Thus, this study aimed to determine whether these polymorphisms in CTLD1 modulate the binding activity and the migratory and proliferative responses to collagen in cells expressing the human variant PLA~2~R. To determine the clinical relevance of this experiment, we tested the possible association of these polymorphisms in CTLD1 of the PLA~2~R gene with peripheral vascular parameters including intima-media thickness (IMT) of the carotid artery, pulse wave velocity (PWV), and ankle-brachial index (ABI) in humans.

Materials and Methods
=====================

Reagents
--------

Human collagen type I from placenta was purchased from BD Biosciences (Bedford, MD, USA). Antibody against CTLD5--6 of human PLA~2~R was purchased from GeneTex (Irvine, CA, USA). Sodium \[^125^I\]-iodine (carrier-free, 3.7 GBq/mL) was purchased from Perkin Elmer (Boston, MA, USA).

Generation of cDNA Constructs Encoding Human Wild-Type and Mutant PLA~2~R
-------------------------------------------------------------------------

Human PLA~2~R wild-type plasmid (NM_001195641) was purchased from Origene (Rockville, MD, USA). The PLA~2~R cDNA was removed from the original vector and inserted into the pBA po-CMV vector. Mutations inCTLD1 of wild-type PLA~2~R were made using a QuikChange II Site-Directed Mutagenesis Kit and primers from Agilent (Santa Clara, CA, USA). The mutagenesis primers are described in **[Supplemental Table 1](#T4){ref-type="table"}**. pcDNAs of all constructs were transformed into *Escherichia coli* One Shot TOP10 cells from Invitrogen (Carlsbad, CA, USA) and purified using a QIAfilter Plasmid Kit from QIAGEN (Valencia, CA, USA). Further, the DNA sequences were checked to exclude sequence errors.

Cell Lines and Transfection
---------------------------

The human embryonic kidney cell line (HEK293) (ECACC No. EC85120602) was maintained in Dulbecco\'s modified Eagle\'s medium (DMEM) (Life Technologies, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Life Technologies). Lipofectamine 2000 (Life Technologies) was used to mediate transient transfection according to the manufacturer\'s protocol^[@bib9])^.

Cell Migration Assay
--------------------

Migration assays were performed using modified Boyden chamber with polycarbonate filters (pore size, 8 *µ*m) (Corning, NY, USA) for 24-well trays in which the bottom surface was precoated with collagen I (10 *µ*g/mL) (BD Biosciences, MD, USA) or PBS as a vehicle control for 1 h^[@bib9],\ [@bib12])^. Cells (2 × 10^5^) were suspended in serum-free DMEM containing 0.5% BSA and placed in the upper chamber. Incubation lasted 3 h at 37°C in 5% CO~2~. On incubation, cells on the upper surface were removed by scraping, and cells adherent to the bottom surface of the filter were fixed in methanol and stained with a Diff Quik kit (Sysmex, Hyogo, Japan) for counting. The number of migrating cells was determined by counting 5 fields randomly selected from each filter with an optical microscope at a magnification of 100×. Each experiment was per-formed in triplicate and migration was expressed as the average number of total cells counted per field.

Proliferation Assay
-------------------

Proliferation of transfected HEK293 cells (as determined by DNA synthesis) was measured by a colorimetric bromodeoxyuridine (BrdU) assay kit from Roche (Mannheim, Germany) according to the manufacturer\'s protocol. Transfected HEK293 cells were seeded in a 96-well plate coated with collagen I or PBS (as a control) (2 × 10^4^ cells/well). The BrdU reagent was added for 2 h according to the provided protocol. Proliferation was measured by light absorbance at 370/492 nm.

Binding Assay
-------------

Collagen I in Tris buffer (25 mM Tris-HCl, pH 7.5, 0.4 mM NaCl) was labeled with 30 MBq of Na^125^I (Perkin Elmer, MA, USA) in precoated iodination tubes (Thermo Scientific, MA, USA), as described in our previous report^[@bib9])^. For binding assays, transfected HEK293 cells were incubated on 24-well plates with the indicated concentrations of ^125^I-labeled collagen I in the absence or presence of a 50-fold excess of unlabeled collagen I for 2 h at 4°C. After the reaction, the cells were washed 3 times with ice-cold PBS, and the cell-associated radioactivity was measured with a gamma counter. The specific binding was defined as the difference between binding in the presence and absence of the unlabeled collagen I, which was the difference between the total binding and non-specific binding.

Sources of Cultures of Human Umbilical Vein Endothelial Cells and Human Vascular Smooth Muscle Cells
----------------------------------------------------------------------------------------------------

Human umbilical vein endothelial cells (HUVECs) were obtained from ATCC (Manassas, VA, USA) and cultured with F-12K Nutrient Mixture (ATCC) supplemented with 10% FBS, 0.03 mg/dL endothelial cell growth supplement (Sigma, St. Louis, MO, USA), and 0.5 mg/dL heparin (Sigma). Human vascular smooth muscle cells (SMCs) were from Lonza (Walkersville, MD, USA) and cultured with DMEM supplemented with 10% FBS. HUVECs and human vascular SMCs at confluent condition were used for the measurement of PLA~2~R mRNA expression.

Measurements of mRNA
--------------------

The mRNA expression levels were quantified with a real-time two-step reverse transcriptase polymerase chain reaction (PCR) assay using TaqMan chemistry and a 7500 Real-Time PCR System (Applied Biosystems, CA, USA). The primers were predesigned by TaqMan Gene Expression Assays (Applied Biosystems) (Hs00234853_m1).

Western Blotting Analysis
-------------------------

Immunoblotting analyses were performed to detect human PLA~2~R protein expression in transfected cells using polyclonal antibody against CTLD5--6 of human PLA~2~R (GeneTex). Protein (10 *µ*g) from the extracts of transfected cells were separated by SDSPAGE and transferred to a polyvinylidene difluoride membrane. The membrane was treated with blocking buffer and incubated overnight at 4°C with the antibody against human PLA~2~R.

Flow Cytometric Analysis
------------------------

Flow cytometry was performed using the FACS-Caliber. Transfected HEK293 cells were suspended (2×10^6^ cells/tube) in PBS/0.1% FBS/0.09% NaN~3~ and incubated with the antibody against CTLD5--6 of human PLA~2~R (GeneTex)for 30 min at 4°C. After the washing step in PBS/0.1% FBS/0.09% NaN~3~, the cells were incubated with anti-goat IgG-Alexa 647 antibody (1:100 dilution) (Life Technologies). We set an isotype-matched IgG as a control.

Patients for Clinical Study
---------------------------

The clinical study screened 941 consecutively-enrolled patients with chest pain who underwent cardiac catheterization at Yamanashi University Hospital from April 2002 to March 2011. The patients had routine non-invasive vascular measurements including intima-media thickness (IMT) of the carotid artery, brachial-ankle pulse wave velocity (baPWV), and ankle-brachial index (ABI). This study excluded 16 patients who had none of these vascular measurements; thus, 925 patients (580 men) were included in this study. The characteristics of the patients are shown in **[Table 1](#T1){ref-type="table"}**. The patients provided written informed consent for the study before enrollment. The study was approved by the ethics committee of Yamanashi University Hospital. The investigation conformed to the principles outlined in the 1975 Declaration of Helsinki.

###### Baseline characteristics of the enrolled patients

                             Total patients (*n* = 925)   Men (*n* = 580)        Women (*n* = 345)
  -------------------------- ---------------------------- ---------------------- ----------------------
  Age, (y)                   64.4 (57.3--74.0)            57.3 (55.4--72.8)      69.7 (61.9--75.5)
  Smoking, *n* (%)           90 (9.7)                     82 (14.1)              8 (2.3)
  DM, *n* (%)                300 (32.4)                   209 (36.0)             91 (26.4)
  Hypertension, *n* (%)      473 (51.1)                   295 (50.9)             178 (51.6)
  BMI, (kg/m^2^)             23.8 ± 3.4                   24.0 ± 3.1             23.6 ± 3.8
  MI, *n* (%)                265 (28.6)                   198 (34.1)             67 (19.4)
  Stroke, *n* (%)            63 (6.8)                     42 (7.2)               21 (6.1)
  HbA1c, (%)                 5.6 (5.2--6.2)               5.6 (5.3--6.4)         5.6 (5.2--6.0)
  CRP, (mg/L)                0.2 (0.1--0.3)               0.2 (0.1--0.3)         0.2 (0.1--0.3)
  eGFR, (ml/min/1.73 m^2^)   69.1 (52.4--90.6)            73.4 (55.8--95.5)      62.0 (47.9--79.9)
  TG, (mg/dL)                121.0 (88.0--167.0)          126.0 (93.0--172.0)    111.0 (80.5--147.0)
  HDL-C, (mg/dL)             47.0 (39.0--57.0)            45.0 (37.0--54.0)      53.0 (43.0--66.0)
  LDL-C, (mg/dL)             120.6 (98.0--143.8)          116.2 (95.8--142.6)    123.3 (102.6--147.2)
  Non HDL-C, (mg/dL)         147.0 (121.0--174.0)         146.0 (119.0--174.0)   149.5 (125.0--174.0)
  maxIMT, (mm)               0.9 (0.7--1.4)               0.9 (0.7--1.5)         0.9 (0.7--1.4)
  ABI                        1.0 (0.9--1.0)               1.0 (0.9--1.0)         1.0 (0.9--1.0)
  baPWV, (m/sec)             16.2 (13.9--19.0)            15.9 (13.6--18.8)      16.6 (14.7--19.8)

Data given as mean ± SD, median (IQR) or *n* (%).

ABI, ankle-brachial index; baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; CRP, C-reactive protein; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; maxIMT, maximum intima-media thickness; LDL-C, low-density lipoprotein cholesterol; MI, history of previous myocardial infarction; stroke, history of stroke; TG, triglyceride.

Genotyping
----------

Genomic DNA was extracted from whole blood samples using a DNA Extractor WB-Rapid Kit (Wako, Osaka, Japan) or a Quick Gene DNA Whole Blood Kit (Fujifilm, Tokyo, Japan) with a Quick Gene-800 (Fujifilm) according to the manufacturer\'s protocol.

The polymorphic regions were amplified with a Taqman SNP genotyping assay with a 7500 Real-Time PCR System using 10 ng genomic DNA in a 20 *µ*L reaction mixture containing 2× FastStart Universal Probe Master (Roche, Mannheim, Germany) and forward and reverse primers, encompassing the polymorphic sites (T/C at rs3749117 and G/C at rs35771982). The primers were predesigned by Taq-Man Gene Expression Assays (Applied Biosystems) (Assay IDs, C_25805618_10 and C_25621628_10, respectively). The amplification protocol consisted of initial denaturation at 95°C for 2 min, followed by 35 cycles of denaturation at 95°C for 30 sec, annealing for 30 sec at the appropriate temperature for the primer pair, extension at 72°C for 30 sec, and final extension at 72°C for 5 min.

Measurement of Intima-Media Thickness of the Carotid Artery
-----------------------------------------------------------

Carotid ultrasound was carried out using an 11.0 MHz, linear-array transducer (SONOS-5500; Phillips, Andover, MA, USA) according to our previous reports^[@bib19]--[@bib21])^. Briefly, 2 well-trained researchers performed all the carotid scans without any information on the patients\' clinical characteristics. Longitudinal images of each carotid artery were used to measure intima-media thickness (IMT), defined as the distance from the leading edge of the lumen-intima interface to the leading edge of the media-adventitia interface. Maximum IMT (maxIMT) was defined as the greatest IMT in the 6 carotid arteries including the common carotid artery, bifurcation, and proximal internal carotid artery of right and left sides. The cutoff value of 1.1 mm was derived from previous reports^[@bib19]--[@bib22])^. In our study, the mean biases of the inter- and intraobserver for repeated measurements of maxIMT in 20 patients extracted at random were 0.02 ± 0.24 mm and 0.01 ± 0.17 mm, respectively.

Measurement of Brachial-Ankle Pulse Wave Velocity
-------------------------------------------------

We measured brachial-ankle pulse wave velocity (baPWV) by a volume plethysmographic method using an automatic waveform analyzer (VP-1000; Colin Co. Ltd., Komaki, Japan), according to previous reports^[@bib21],\ [@bib23])^. baPWV was calculated by measuring the time for the pulse wave to travel between the brachial and posterior tibial arteries. The mean value of the left and right baPWV was used in the statistical analyses. Inter- and intra-observer variabilities for repeated baPWV measurements in 20 patients on separate days were 0.62 ± 0.31 m/sec and 0.53 ± 0.26 m/sec, respectively. The 75^th^ percentile value of baPWV (19 m/sec) in the distribution of baPWV value in the study patient population was selected as a cutoff in this study.

Measurement of Ankle-Brachial Index
-----------------------------------

Systolic blood pressure was measured in all 4 extremities using an oscillometric device (VP-1000; Colin Co. Ltd., Komaki, Japan). Resting ankle-brachial index (ABI) was calculated by dividing the higher value of the 2 ankle systolic blood pressures in each leg (dorsalis pedis or posterior tibial artery) by the higher value of systolic blood pressures in the 2 brachial arteries. The selected ABI was the lower of the values for the left and right legs. The inter- and intra-observer variability for the repeated measurements of ABI in 20 patients on separate days was 0.011 ± 0.10 and 0.008 ± 0.08, respectively. The 25^th^ percentile value of ABI (0.88) in the distribution of ABI value in the study patient population was selected as a cutoff for analysis in this study.

Statistical Analysis
--------------------

All descriptive data are expressed as either means ± SD or median, or frequency (%) as indicated. The Shapiro--Wilk test showed that age, estimated glomerular filtration rate (eGFR), maxIMT, ABI, baPWV, and levels of HbA1c, C-reactive protein, triglycerides, HDL-cholesterol (C), LDL-C, and non HDL-C were not distributed normally. Therefore, these variables were expressed as the median and interquartile range (25^th^ and 75^th^ percentiles). Statistical relationships were assessed on univariate or multivariate logistic analysis. Multivariate logistic regression analysis was conducted using confounders that were significant in the univariate model. Univariate and multivariate logistic regression analysis examined 1-SD changes in continuous variables. The presence of dichotomous variables was coded as 1 and the absence as 0. D' statistics and correlation coefficient (r statistics) were used to investigate the linkage disequilibrium between T/C at rs3749117 and G/C at rs35771982 polymorphisms of PLA~2~R. To assess the effect of different alleles on the vascular parameters, logistic regression analysis was employed in 5 inheritance models: codominant, dominant, recessive, over-dominant, and log-additive.

All probabilities were expressed as two-tailed, with statistical significance inferred at *p* \< 0.05. All confidence intervals were computed at the 95% level. Statistical analysis was conducted using STATA 10.0 (StataCorp, College Station, TX, USA).

Results
=======

Human PLA~2~R Expression in Transfected HEK293 Cells
----------------------------------------------------

As previously reported^[@bib17],\ [@bib18])^, two nonsynonymous polymorphisms (T/C at rs3749117 and G/C at rs35771982) were identified in the CTLD1 region of the PLA~2~R gene in the study patient population (**[Fig. 1](#F1){ref-type="fig"}**). The two polymorphisms were completely linked (D\' statistics = 1, r statistics = 1). Thus, we produced HEK293 cells expressing human wild-type PLA~2~R (T at rs3749117 and G at rs35771982) or mutant PLA~2~R that had double mutations in CTLD1 of human PLA~2~R (C at rs3749117 and C at rs35771982). In immunoblotting experiments, the apparent molecular weights of wild-type and mutant human PLA~2~Rs were consistent with their calculated molecular weights (**[Fig. 2A](#F2){ref-type="fig"}**). The extent of wild-type and mutant type PLA~2~R protein expression was similar (**[Fig. 2B](#F2){ref-type="fig"}**). Flow cytometric analysis confirmed wild-type and mutant PLA~2~R cell surface expression (**[Fig. 2C](#F2){ref-type="fig"}**). The mean fluorescence intensity (MFI) was similar in cells expressing wild-type and mutant type PLA~2~R (**[Fig. 2D](#F2){ref-type="fig"}**). HEK293 cells expressed only faint levels of mRNA of endogenous PLA~2~R (per GAPDH mRNA expression; 4 × 10^−4^ at 35 PCR cycles). After transfection with a construct encoding wild-type PLA~2~R, PLA~2~R mRNA and cell surface protein expression increased approximately 6 × 10^3^-fold compared with transfection with an empty vector (data not shown).

![Wild-type and mutant human PLA~2~R protein expression in transfected HEK293 cells\
(A) Western blot analysis of wild-type and mutant PLA~2~R expressed in HEK293 cells using polyclonal antibody for against CTLD5--6 of human PLA~2~R. The apparent molecular weights of wild-type and mutant PLA~2~R are consistent with their calculated molecular weights, indicating efficient translation. No protein band was detected in control mock-transfected cells (mock). (B) Quantitative analysis of the immunoblotting. Protein expression levels of wild-type and mutant PLA~2~R were similar in HEK293 cells transfected with the respective genotypes. (C) Flow cytometric analyses of wild-type and mutant PLA~2~R cell surface expression in HEK293 cells transfected with a cDNA construct encoding wild-type and mutant PLA~2~R using polyclonal antibody against CTLD5--6 of human PLA~2~R. Upper panels, representative dot plots of suspensions of HEK293 cells transfected with wild-type or mutant PLA~2~R; lower panels, representative histograms studying PLA~2~R expression on cells transfected with the respective PLA~2~R genotypes. (D) Comparison of mean fluorescence intensity (MFI) for PLA~2~R expression in HEK293 cells transfected with wild-type or mutant PLA~2~R. (E) PLA~2~R expression in cultures of human umbilical vein endothelial cells (HUVECs), human vascular smooth muscle cells (SMCs), and mock. The mRNA expression levels were quantified with a real-time two-step reverse transcriptase PCR assay. *n* = 7 in each experiment. NS, statistically not significant.](jat-23-1227-g002){#F2}

Migration Assay
---------------

In the Boyden chamber experiments, HEK293 cells migrated on filters precoated with human collagen I, but not on plain membranes (PBS coating, as a control), regardless of the PLA~2~R expression (**[Fig. 3A](#F3){ref-type="fig"}**). Cells expressing wild-type PLA~2~R showed greater migration on filters with collagen I than the control mock-transfected cells (mock) (**[Fig. 3A](#F3){ref-type="fig"}**). In contrast, cells expressing double mutant PLA~2~R showed lower migratory responses to collagen I than mock.

![Comparison of migration, proliferation, and binding to human collagen I between HEK293 cells expressing wild-type PLA~2~R and double mutant PLA~2~R (C at rs3749117 and C at rs35771982)\
(A) Migration of HEK293 cells expressing wild-type or double mutant type of PLA~2~R on filter membranes coated with PBS (as a control) or collagen I (Coll) in Boyden chamber experiments. (B) Proliferation (measured by light absorbance at 370/492 nm) of cells expressing wild-type or double mutant type of PLA~2~R on dishes coated with PBS or collagen I (Coll). (C) Binding activity to collagen I in cells expressing wild-type or double mutant type of PLA~2~R. Cells were incubated with ^125^I-labeled collagen I at 4°C in the absence or presence of a 50-fold excess amount of unlabeled collagen I and washed with cold PBS. The radioactivity of collagen I bound to cells (counts per minute in 100 *µ*g of protein) is shown after correcting for nonspecific binding. \* *p* \< 0.05 in comparison with mock; ^†^ *p* \< 0.05 between wild-type; and double mutant type of PLA~2~R. ^\#^ \< 0.05 in comparison with respective genotypes of cells on PBS-coated dishes. *n* = 6 for each experiment.](jat-23-1227-g003){#F3}

Proliferation Assay
-------------------

Proliferative response was increased in all genotypes of the transfected cells on the collagen I-coated dishes compared with the respective genotypes of cells on dishes coated with PBS as a control (**[Fig. 3B](#F3){ref-type="fig"}**). Cells expressing wild-type or double mutant PLA~2~R showed a decrease in proliferative response to collagen I compared with mock (**[Fig. 3B](#F3){ref-type="fig"}**). Cells expressing double mutant PLA~2~R showed a greater decrease in proliferative response to collagen I than those expressing wild-type PLA~2~R. The proliferative response on PBS-coating dishes was similar for wild-type and mutant PLA~2~R or mock (**[Fig. 3B](#F3){ref-type="fig"}**).

Binding Assay
-------------

As shown in **[Fig. 3C](#F3){ref-type="fig"}**, HEK293 cells expressing either wild-type or double mutant PLA~2~R showed increased binding to human collagen I compared with mock. Cells expressing double mutant PLA~2~R had less binding to collagen I compared with those expressing wild-type PLA~2~R (**[Fig. 3C](#F3){ref-type="fig"}**).

Migratory, Proliferative and Binding Activities in Cells Expressing Single Mutant PLA~2~R
-----------------------------------------------------------------------------------------

We produced HEK293 cells expressing mutant PLA~2~R that had a single mutation in CTLD1 of human PLA~2~R (either C at rs3749117 \[Singl Mut1\] or C at rs35771982 \[Singl Mut2\]). HEK293 cells expressing single mutant PLA~2~R at either C at rs3749117 or C at rs35771982 showed lower migratory (**[Fig. 4A](#F4){ref-type="fig"}**), proliferative (**[Fig. 4B](#F4){ref-type="fig"}**), and binding activity (**[Fig. 4C](#F4){ref-type="fig"}**) compared with those expressing wild-type PLA~2~R.

![Comparison of migration, proliferation, and binding to human collagen I between HEK293 cells expressing wild-type PLA~2~R and single mutant PLA~2~R (either C at rs3749117 \[Singl Mut1\] or C at rs35771982 \[Singl Mut2\])\
(A) Migration of HEK293 cells expressing wild-type or single mutant type of PLA~2~R. (B) Proliferation of cells expressing wild-type or single mutant type of PLA~2~R. (C) Binding activity to collagen I in cells expressing wild-type or single mutant type of PLA~2~R. \* *p* \< 0.05 in comparison with mock; ^†^ *p* \< 0.05 between wild type; and single mutant type of PLA~2~R. ^\#^ \<0.05 in comparison with respective genotypes of cells on PBS-coated dishes. *n* = 6 for each experiment.](jat-23-1227-g004){#F4}

PLA~2~R Expression in Cultures of HUVECs and human vascular SMCs
----------------------------------------------------------------

We examined PLA~2~R mRNA expression in cells from human vessels. As shown in **[Fig. 2E](#F2){ref-type="fig"}**, PLA~2~R was substantially expressed in cultures of HUVECs and human vascular SMCs. The extent of PLA~2~R expression in cultures of HUVECs and human vascular SMCs was approximately 100 times less than that in the HEK293 cells overexpressing wild-type PLA~2~R (data not shown).

Relation between PLA~2~R Gene Polymorphism and maxIMT of the Carotid Artery, baPWV, or ABI in Humans
----------------------------------------------------------------------------------------------------

As previously reported^[@bib17],\ [@bib18])^, two polymorphisms (T/C at rs3749117 and G/C at rs35771982) were identified in the CTLD1 region of the PLA~2~R gene (**[Fig. 1](#F1){ref-type="fig"}**). The 2 polymorphisms were completely linked (D\' statistics = 1, r statistics = 1). The distribution of the genotypes was consistent with a Hardy-Weinberg equilibrium in the population (exact test, *p* = 0.79). Because the 2 polymorphisms were completely linked, we chose the T/C at rs3749117 polymorphism for further statistical analyses. Logistic regression analysis showed that there were significant relationships between PLA~2~R polymorphism and the increased maxIMT of the carotid artery in codominant and recessive models in a subgroup of male patients, but not female patients and total patients (**[Table 2](#T2){ref-type="table"}, [Supplemental Tables 2](#T5){ref-type="table"}** and **[3](#F3){ref-type="fig"}**). Representative ultrasound images of the carotid artery are shown in **[Fig. 5](#F5){ref-type="fig"}**. There was no significant relationship between PLA~2~R polymorphism and baPWV or ABI in either total patients or the subgroups of male or female patients (**[Supplemental Tables 4](#T7){ref-type="table"}--[9](#T12){ref-type="table"}**). We determined whether PLA~2~R polymorphism could be a risk for increased maxIMT of the carotid artery in the male subgroup. In multivariate logistic regression, the CC genotype at rs3749117 of PLA~2~R gene was a significant risk factor of an increased maxIMT of the carotid artery that was independent of other conventional risk factors (OR = 1.93, 95% CI: 1.17--3.19, *p* \< 0.01) (**[Table 3](#T3){ref-type="table"}**).

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and an increased maxIMT in male patients

  ----------------------------------------------------------------------------------------------
                  Genotypes   maxIMT \< 1.1 mm   maxIMT ≥ 1.1 mm   OR (95% CI)          *p*
  --------------- ----------- ------------------ ----------------- -------------------- --------
  Codominant      T/T\        98 (37.0)\         113 (35.9)\       1.00\                0.026
                  C/T\        138 (52.1)\        143 (45.4)\       0.90 (0.63--1.29)\   
                  C/C         29 (10.9)          59 (18.7)         1.76 (1.05--2.97)    

  Dominant        T/T\        98 (37.0)\         113 (35.9)\       1.00\                0.78
                  C/T-C/C     167 (63.0)         202 (64.1)        1.05 (0.75--1.47)    

  Recessive       T/T-C/T\    236 (89.1)\        256 (81.3)\       1.00\                0.0085
                  C/C         29 (10.9)          59 (18.7)         1.88 (1.38--2.86)    

  Over-dominant   T/T-C/C\    127 (47.9)\        172 (54.6)\       1.00\                0.11
                  C/T         138 (52.1)         143 (45.4)        0.77 (0.55--1.06)    

  Log-additive    \-\--       \-\--              \-\--             1.21 (0.95--1.54)    0.12
  ----------------------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

![Representative ultrasonic images of carotid arteries in patients with C/C (A), C/T (B), or T/T (C) at rs3749117\
CCA = common carotid artery; ICA = internal carotid artery. White dotted lines indicate margin of plaque or IMT of the carotid arteries](jat-23-1227-g005){#F5}

###### Univariate and multivariate logistic regression analysis of association of C/C genotype at rs3749117 of PLA~2~R gene and cardiovascular risk factors with an increased maxIMT of the carotid artery in male patients

                 Univariate   Multivariate                                 
  -------------- ------------ -------------- -------- ------- ------------ --------
  Smoking        0.82         0.51--1.30     0.40     \-\--   \-\--        \-\--
  DM             1.88         1.32--2.66     \<0.01   1.59    0.97--2.61   0.06
  Hypertension   1.89         1.36--2.54     \<0.01   1.69    1.19--2.39   \<0.01
  BMI            1.02         0.96--1.07     0.53     \-\--   \-\--        \-\--
  HbA1c          1.27         1.10--1.46     \<0.01   1.11    0.92--1.32   0.28
  CRP            1.04         0.95--1.14     0.396    \-\--   \-\--        \-\--
  eGFR           0.97         0.96--0.98     \<0.01   0.98    0.97--0.98   \<0.01
  TG             0.99         0.99--1.00     0.530    \-\--   \-\--        \-\--
  HDL-C          0.99         0.98--1.01     0.270    \-\--   \-\--        \-\--
  LDL-C          1.00         0.99--1.01     0.081    \-\--   \-\--        \-\--
  Non HDL-C      1.00         0.99--1.00     0.193    \-\--   \-\--        \-\--
  C/C            1.88         1.38--2.86     \<0.01   1.93    1.17--3.19   \<0.01

CI, confidence interval; OR, odd ratio. C/C, C/C genotype at rs3749117 of PLA~2~R gene. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

Discussion
==========

The present study showed that two nonsynonymous polymorphisms (T/C at rs3749117 and G/C at rs35771982) in CTLD1 of the PLA~2~R gene were completely linked. Our group and other researchers have previously shown that the FNII domain of PLA~2~R was responsible for binding of PLA~2~R to collagen I and collagen-dependent migration and prolifera-tion^[@bib9],\ [@bib12],\ [@bib13])^. In addition, we demonstrated that the neighboring CTLD1 may modulate the collagen binding activity of the FNII domain^[@bib9])^. The combination of two amino acid substitutions (Met292Val encoded by SNP rs3749117 and His300Asp encoded by rs35771982) could lead to a conformational change in CTLD1. The conformational change in CTLD1 may consequently reduce collagen binding activity of the FNII domain and the migratory and proliferative responses of cells expressing the variant type of human PLA~2~R.

The present study was the first to show that PLA~2~R gene polymorphisms were a genetic risk of an increased maxIMT of the carotid artery. PLA~2~R is expressed in HUVECs and human vascular SMCs. Vascular endothelial cells play a critical role in the restoration of vascular injury that could lead to development of atherosclerosis^[@bib24])^. Endothelial cells expressing variant PLA~2~R may have a reduced ability to restore injured arteries because these endothelial cells may be dysfunctional as suggested by HEK293 cells transfected with the variant PLA~2~R gene. A recent report showed that senescence of vascular SMCs promoted atherosclerosis^[@bib25])^. Senescence of vascular SMCs may have a role in the increased IMT of the carotid artery in patients with the variant PLA~2~R gene because vascular SMCs expressing variant PLA~2~R may have a reduced proliferative activity as suggested by our observation using HEK293 cells. These scenarios may explain the higher prevalence of an increased maxIMT of the carotid artery in male patients with variant PLA~2~R compared with those with wild-type PLA~2~R. The extent of PLA~2~R expression in cultures of HUVECs and human vascular SMCs was approximately 100 times less than that in the HEK293 cells expressing wild-type PLA~2~R. Whether PLA~2~R may be expressed in endothelial cells and vascular SMCs in the arterial walls with high enough extent to exert a physiological role is yet unclear.

A previous report showed that frequencies of each genotype of the polymorphism (rs3749117) were 47.9% in T/T genotype, 44.2% in C/T, and 7.8% in C/C in patients without membrane nephropathy in the Han population^[@bib26])^. Thus, there was similar tendency of genotype frequencies in the polymorphism (rs3749117) between Han population and the present Japanese population. In addition, that previous report showed very similar frequencies between T/T and G/G, T/C and G/C, and C/C and C/C genotypes of rs3749117 and rs35771982, respectively^[@bib26])^, suggesting that the two polymorphisms may also be linked in the Han population. Antiatherosclerotic effects of estrogen may confound the association between PLA~2~R gene polymorphisms and an increased maxIMT of the carotid artery in female patients, which may explain the inability to demonstrate an association in female patients and within the total patient population. A decrease of ABI reflects a late stage of atherosclerosis^[@bib27])^. PWV reflects arterial stiffening that is increased by adverse structural and functional alterations in the vascular wall^[@bib27])^. These arterial tests evaluate different stages of arterial damage at different arterial sites^[@bib21])^. These may account for the absence of an association between PLA~2~R gene polymorphisms and baPWV or ABI in the present study. The inverse association between an estimated glomerular filtration rate (eGFR) and IMT of the carotid artery is consistent with the data in a previous report^[@bib28])^ that showed renal dysfunction is associated with carotid atherosclerosis.

Previous studies showed that patients with IMN were associated with the same nonsynonymous variants (Met292Val or His300Asp) in the CTLD1 of PLA~2~R gene with regard to an increased maxIMT of the carotid artery in the present study^[@bib17],\ [@bib18])^. It is hypothesized that the amino acid substitution Met292Val or His300Asp could lead to a conformational change in CTLD1 of PLA~2~R, resulting in its function as an antigen^[@bib17],\ [@bib18])^.

The present study was the first to show that the two variants were completely linked. It may be expected that simultaneous substitution of Met292Val and His300Asp in PLA~2~R could induce a conformational change with greater extent than single substitution of each variant. However, HEK293 cells expressing single mutant PLA~2~R similarly decreased the bio-logical responses similar to those expressing double mutant PLA~2~R. The mechanisms underlying the association between these gene variants and functional changes in cells expressing these variants remain largely undefined. We cannot exclude the possibility that this polymorphism is a marker for another functional variant within this or adjacent genes. A recent paper failed to show a greater binding of the variant PLA~2~R to the autoantibody in IMN patients than wild-type PLA~2~R^[@bib15])^. In that experiment, the variant PLA~2~R was prepared by individual substitution of Met-292 with Val or of His-300 with Asp in wild-type PLA~2~R^[@bib15])^. Whether simultaneous substitution of Met292Val and His300Asp in PLA~2~R shows a greater antigenicity of these variants than wild-type PLA~2~R is yet unclear.

The present study showed that human PLA~2~R inhibited the cells\' proliferative response independent of its gene polymorphisms. This observation is in agreement with a previous report^[@bib11])^ showing that human PLA~2~R promoted senescence in fibroblasts. In contrast, mouse PLA~2~R increased the proliferative response to collagen I^[@bib9],\ [@bib12])^. The reason for this discrepancy in the proliferative response between human and mouse PLA~2~R is unknown. Moreover, higher binding activity to collagen was associated with lower proliferative response in the cells expressing wild-type human PLA~2~R compared with mock cells. Thus, human PLA~2~R-mediated migratory and proliferative response may not necessarily depend on collagen binding. Although the exact mechanisms for human PLA~2~R-mediated biological responses remain unknown, human PLA~2~R promotes senescence in fibroblasts and induces cancer cell death through a JAK2-mediated mechanism^[@bib10],\ [@bib11])^.

Conclusions
===========

Two nonsynonymous common variants (Met292Val at rs3749117 and His300Asp at rs35771982) in the CTLD1 of the PLA~2~R gene present a genetic risk for an increase in IMT of the carotid artery. These variants in the PLA~2~R gene were completely linked. The simultaneous substitution of the two amino acids (Met292Val and His300Asp) in PLA~2~R inhibited binding, migratory, and proliferative responses to collagen I in cells expressing the variant PLA~2~R. The functional changes associated with the amino acid substitutions in the variant PLA~2~R may be potentially responsible for the association between an increase in IMT of the carotid artery and polymorphisms in the PLA~2~R gene.
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###### Primers used for point mutagenesis of T/C at rs3749117 and G/C at rs35771982 of PLA~2~R gene

                     Forward                             Reverse
  ------------------ ----------------------------------- -----------------------------------
  rs3749117 (T/C)    5′AGTGGAGGTGTGGGTGGGCCTCAATCAGC3′   5′GCTGATTGAGGCCCACCCACACCTCCACT3′
  rs35771982 (G/C)   5′ATCAGCTGGATGAAGACGCTGGCTGGCAG3′   5′CTGCCAGCCAGCGTCTTCATCCAGCTGAT3′

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and an increased maxIMT of the carotid artery in total patient population

  --------------------------------------------------------------------------------------------
                  Genotypes   maxIMT \< 1.1 mm   maxIMT ≥ 1.1 mm   OR (95% CI)          *p*
  --------------- ----------- ------------------ ----------------- -------------------- ------
  Codominant      T/T\        152 (33.8)\        170 (35.8)\       1.00\                0.23
                  C/T\        227 (50.4)\        215 (45.3)\       0.85 (0.64--1.13)\   
                  C/C         71 (15.8)          90 (18.9)         1.13 (0.77--1.66)    

  Dominant        T/T\        152 (33.8)\        170 (35.8)\       1.00\                0.52
                  C/T-C/C     298 (66.2)         305 (64.2)        0.92 (0.70--1.20)    

  Recessive       T/T-C/T\    379 (84.2)\        385 (81.0)\       1.00\                0.20
                  C/C         71 (15.8)          90 (18.9)         1.25 (0.89--1.76)    

  Over-dominant   T/T-C/C\    223 (49.6)\        260 (54.7)\       1.00\                0.11
                  C/T         227 (50.4)         215 (45.3)        0.81 (0.63--1.05)    

  Log-additive    \-\--       \-\--              \-\--             1.02 (0.85--1.23)    0.80
  --------------------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and an increased maxIMT in female patients

  ----------------------------------------------------------------------------------------------
                 Genotypes      maxIMT \< 1.1 mm   maxIMT ≥ 1.1 mm   OR (95% CI)          *p*
  -------------- -------------- ------------------ ----------------- -------------------- ------
  Codominant     T/T\           55 (29.6)\         59 (37.1)\        1.00\                0.31
                 C/T\           91 (48.9)\         67 (42.1)\        0.69 (0.42--1.11)\   
                 C/C            40 (21.5)          33 (20.8)         0.77 (0.43--1.39)    

  Dominant       T/T\           55 (29.6)\         59 (37.1)\        1.00\                0.14
                 C/T-C/C        131 (70.4)         100 (62.9)        0.71 (0.45--1.12)    

  Recessive      T/T-C/T TC/C   146 (78.5)\        126 (79.2)\       1.00\                0.86
                                40 (21.5)          33 (20.8)         0.96 (0.57--1.61)    

  Overdominant   T/T-C/C\       95 (51.1)\         92 (57.9)\        1.00\                0.21
                 C/T            91 (48.9)          67 (42.1)         0.76 (0.50--1.16)    

  Log-additive   \-\--          \-\--              \-\--             0.85 (0.64--1.14)    0.29
  ----------------------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and an increased baPWV (≥ 19 m/sec) in total patient population

  ---------------------------------------------------------------------------------------------
                 Genotypes   baPWV \< 19 m/sec   baPWV ≥ 19 m/sec   OR (95% CI)          *p*
  -------------- ----------- ------------------- ------------------ -------------------- ------
  Codominant     T/T\        245 (35.0)\         77 (34.4)\         1.00\                0.35
                 C/T\        341 (48.6)\         101 (45.1)\        0.94 (0.67--1.32)\   
                 C/C         115 (16.4)          46 (20.5)          1.27 (0.83--1.95)    

  Dominant       T/T\        245 (35.0)\         77 (34.4)\         1.00\                0.87
                 C/T-C/C     456 (65.0)          147 (65.6)         1.03 (0.75--1.41)    

  Recessive      T/T-C/T\    586 (83.6)\         178 (79.5)\        1.00\                0.16
                 C/C         115 (16.4)          46 (20.5)          1.32 (0.90--1.93)    

  Overdominant   T/T-C/C\    360 (51.4)\         123 (54.9)\        1.00\                0.35
                 C/T         341 (48.6)          101 (45.1)         0.87 (0.64--1.17)    

  Log-additive   \-\--       \-\--               \-\--              1.10 (0.89--1.36)    0.38
  ---------------------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and a decreased ABI (\<0.88) in total patient population

  ----------------------------------------------------------------------------------
                 Genotypes   ABI ≥ 0.88    ABI \<0.88    OR (95% CI)          *p*
  -------------- ----------- ------------- ------------- -------------------- ------
  Codominant     T/T\        224 (33.3)\   98 (38.9)\    1.00\                0.13
                 C/T\        335 (49.8)\   107 (42.5)\   0.73 (0.53--1.01)\   
                 C/C         114 (16.9)    47 (18.6)     0.94 (0.62--1.43)    

  Dominant       T/T\        224 (33.3)\   98 (38.9)\    1.00\                0.11
                 C/T-C/C     449 (66.7)    154 (61.1)    0.78 (0.58--1.06)    

  Recessive      T/T-C/T\    559 (83.1)\   205 (81.3)\   1.00\                0.54
                 C/C         114 (16.9)    47 (18.6)     1.12 (0.77--1.64)    

  Overdominant   T/T-C/C\    338 (50.2)\   145 (57.5)\   1.00\                0.10
                 C/T         335 (49.8)    107 (42.5)    0.74 (0.56--1.00)    

  Log-additive   \-\--       \-\--         \-\--         0.92 (0.75--1.14)    0.45
  ----------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and an increased baPWV (≥ 19 m/sec) in male patients

  -----------------------------------------------------------------------------------------
                 Genotypes   PWV \< 19 m/sec   PWV ≥ 19 m/sec   OR(95% CI)           *p*
  -------------- ----------- ----------------- ---------------- -------------------- ------
  Codominant     T/T\        163 (37.4)\       48 (33.3)\       1.00\                0.68
                 C/T\        208 (47.7)\       73 (50.7)\       1.19 (0.78--1.81)\   
                 C/C         65 (14.9)         23 (16.0)        1.20 (0.68--2.13)    

  Dominant       T/T\        163 (37.4)\       48 (33.3)\       1.00\                0.38
                 C/T-C/C     273 (62.6)        96 (66.7)        1.19 (0.80--1.78)    

  Recessive      T/T-C/T\    371 (85.1)\       121 (84.0)\      1.00\                0.76
                 C/C         65 (14.9)         23 (16.0)        1.08 (0.65--1.82)    

  Overdominant   T/T-C/C\    228 (52.3)\       71 (49.3)\       1.00\                0.53
                 C/T         208 (47.7)        73 (50.7)        1.13 (0.77--1.64)    

  Log-additive   \-\--       \-\--             \-\--            1.11 (0.85--1.46)    0.44
  -----------------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and a decreased ABI (\<0.88) in male patients

  ----------------------------------------------------------------------------------
                 Genotypes   ABI ≥ 0.88    ABI \< 0.88   OR (95% CI)          *p*
  -------------- ----------- ------------- ------------- -------------------- ------
  Codominant     T/T\        156 (34.8)\   55 (41.7)\    1.00\                0.27
                 C/T\        225 (50.2)\   56 (42.4)\    0.71 (0.46--1.08)\   
                 C/C         67 (15.0)     21 (15.9)     0.89 (0.50--1.59)    

  Dominant       T/T\        156 (34.8)\   55 (41.7)\    1.00\                0.15
                 C/T-C/C     292 (65.2)    77 (58.3)     0.75 (0.50--1.11)    

  Recessive      T/T-C/T\    381 (85.0)\   111 (84.1)\   1.00\                0.79
                 C/C         67 (15.0)     21 (15.9)     1.08 (0.63--1.83)    

  Overdominant   T/T-C/C\    223 (49.8)\   76 (57.6)\    1.00\                0.11
                 C/T         225 (50.2)    56 (42.4)     0.73 (0.49--1.08)    

  Log-additive   \-\--       \-\--         \-\--         0.88 (0.66--1.17)    0.38
  ----------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and an increased baPWV (\<19.0 m/sec) in female patients

  ---------------------------------------------------------------------------------------------
                 Genotypes   baPWV \< 19 m/sec   baPWV ≥ 19 m/sec   OR (95% CI)          *p*
  -------------- ----------- ------------------- ------------------ -------------------- ------
  Codominant     T/T\        74 (31.5)\          40 (36.4)\         1.00\                0.22
                 C/T\        115 (48.9)\         43 (39.1)\         0.69 (0.41--1.16)\   
                 C/C         46 (19.6)           27 (24.6)          1.09 (0.59--2.00)    

  Dominant       T/T\        74 (31.5)\          40 (36.4)\         1.00\                0.37
                 C/T-C/C     161 (68.5)          70 (63.6)          0.80 (0.50--1.29)    

  Recessive      T/T-C/T\    189 (80.4)\         83 (75.5)\         1.00\                0.30
                 C/C         46 (19.6)           27 (24.6)          1.34 (0.78--2.30)    

  Overdominant   T/T-C/C\    120 (51.1)\         67 (60.9)\         1.00\                0.09
                 C/T         115 (48.9)          43 (39.1)          0.67 (0.42--1.06)    

  Log-additive   \-\--       \-\--               \-\--              1.00\                0.99
                                                                    (0.73--1.37)         
  ---------------------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.

###### Relationships between T/C genotypes at rs3749117 of PLA~2~R gene and a decreased ABI (\<0.88) in female patients

  ----------------------------------------------------------------------------------
                 Genotypes   ABI ≥ 0.88    ABI \< 0.88   OR (95% CI)          *p*
  -------------- ----------- ------------- ------------- -------------------- ------
  Codominant     T/T\        76 (30.5)\    38 (39.6)\    1.00\                0.19
                 C/T\        121 (48.6)\   37 (38.5)\    0.61 (0.36--1.05)\   
                 C/C         52 (20.9)     21 (21.9)     0.81 (0.43--1.53)    

  Dominant       T/T\        76 (30.5)\    38 (39.6)\    1.00\                0.11
                 C/T-C/C     173 (69.5)    58 (60.4)     0.67 (0.41--1.09)    

  Recessive      T/T-C/T\    197 (79.1)\   75 (78.1)\    1.00\                0.84
                 C/C         52 (20.9)     21 (21.9)     1.06 (0.60--1.88)    

  Overdominant   T/T-C/C\    128 (51.4)\   59 (61.5)\    1.00\                0.09
                 C/T         121 (48.6)    37 (38.5)     0.66 (0.41--1.07)    

  Log-additive   \-\--       \-\--         \-\--         0.86 (0.62--1.19)    0.35
  ----------------------------------------------------------------------------------

Data given as *n* (%). CI, confidence interval; OR, odd ratio. Other abbreviations as in [Table 1](#T1){ref-type="table"}.
